Your browser doesn't support javascript.
loading
Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma.
Deutsch, Julie Stein; Lipson, Evan J; Danilova, Ludmila; Topalian, Suzanne L; Jedrych, Jaroslaw; Baraban, Ezra; Ged, Yasser; Singla, Nirmish; Choueiri, Toni K; Gupta, Saurabh; Motzer, Robert J; McDermott, David; Signoretti, Sabina; Atkins, Michael; Taube, Janis M.
Afiliación
  • Deutsch JS; Department of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA.
  • Lipson EJ; Department of Oncology, Johns Hopkins University, Baltimore, MD 21287, USA; The Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD 21287, USA.
  • Danilova L; Department of Oncology, Johns Hopkins University, Baltimore, MD 21287, USA; The Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD 21287, USA.
  • Topalian SL; Department of Surgery, Johns Hopkins University, Baltimore, MD, USA; The Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD 21287, USA.
  • Jedrych J; Department of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA; Department of Dermatology, Johns Hopkins University, Baltimore, MD 21287, USA.
  • Baraban E; Department of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA.
  • Ged Y; Department of Oncology, Johns Hopkins University, Baltimore, MD 21287, USA.
  • Singla N; Department of Oncology, Johns Hopkins University, Baltimore, MD 21287, USA.
  • Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Gupta S; Bristol-Myers Squibb, Princeton, NJ, USA.
  • Motzer RJ; Department of Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • McDermott D; Department of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Signoretti S; Department of Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Atkins M; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.
  • Taube JM; Department of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA; Department of Oncology, Johns Hopkins University, Baltimore, MD 21287, USA; Department of Dermatology, Johns Hopkins University, Baltimore, MD 21287, USA; The Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Johns Hop
Cell Rep Med ; 4(2): 100947, 2023 02 21.
Article en En | MEDLINE | ID: mdl-36812889
ABSTRACT
With a rapidly developing immunotherapeutic landscape for patients with metastatic clear cell renal cell carcinoma, biomarkers of efficacy are highly desirable to guide treatment strategy. Hematoxylin and eosin (H&E)-stained slides are inexpensive and widely available in pathology laboratories, including in resource-poor settings. Here, H&E scoring of tumor-infiltrating immune cells (TILplus) in pre-treatment tumor specimens using light microscopy is associated with improved overall survival (OS) in three independent cohorts of patients receiving immune checkpoint blockade. Necrosis score alone does not associate with OS; however, necrosis modifies the predictive effect of TILplus, a finding that has broad translational relevance for tissue-based biomarker development. PBRM1 mutational status is combined with H&E scores to further refine outcome predictions (OS, p = 0.007, and objective response, p = 0.04). These findings bring H&E assessment to the fore for biomarker development in future prospective, randomized trials, and emerging multi-omics classifiers.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Carcinoma de Células Renales Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Cell Rep Med Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Carcinoma de Células Renales Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Cell Rep Med Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos